Focus on Optimized Dosing of Ibrutinib Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Peter Clark, MA, MD, FRCP: A Payer Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Aug

Today In Oncology

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Related Videos

Peter Clark, MA, MD, FRCP: A Payer Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Large Multicenter Study Evaluates LITT for Primary and Metastatic Brain Tumors

Tissue-Free ctDNA Assay May Help Identify Recurrence Risk in Early Triple-Negative Breast Cancer

Study Evaluates Chemotherapy-Free Quadruplet in HR-Positive, HER2-Positive Metastatic Breast Cancer

In Cancer Trials, Federal and Industry Sponsors Play Complementary Roles

cfDNA Fragmentomics Plus Methylation Analysis May Improve Detection of Precancerous Colorectal Lesions